DR. KAREN K. WONG
DR. KAREN K. WONGPartner
Intellectual Property
Clean Technology IP Counseling & Patents
Energy & Clean Technology
Global Generics
IP Counseling & Patents
Life Sciences
Dr. Karen Wong is a life sciences IP partner at Wilson Sonsini Goodrich & Rosati. Her practice includes freedom-to-operate and due-diligence studies, patent preparation and prosecution, opinion work, litigation strategy, and technology licensing. Karen serves as IP counsel to many venture-backed companies, and has worked on numerous major strategic alliance transactions, acquisitions, spin-outs, and IPOs.
Concentrating on cutting-edge biotechnology, Karen focuses her multidisciplinary practice on a combination of molecular biology, optical physics, chemical engineering, pharmacology, molecular diagnostics, and cellular physiology. She has developed technical expertise in DNA-sequencing techniques and instruments, antibody engineering and design, biofuels, drug delivery systems, gene therapies, cancer treatments, and point-of-care diagnostic tools.
Prior to practicing law, Karen conducted doctoral and postdoctoral research at Harvard and Tufts Medical School in molecular biology, cell biology, and physiology.
Karen is a co-founder and board member of BioE2E, which has built one of the largest communities of life sciences entrepreneurs in the Bay Area. A native of Sichuan, China, she is fluent in English, Mandarin, and Cantonese.
EDUCATION:
- J.D., Santa Clara University School of Law
- Ph.D., Cellular and Molecular Physiology, Tufts University
Postdoctoral fellow at Harvard Medical School - B.A., Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder
- Major in Biology, Chinese University of Hong Kong
Minor in Business Administration
- Co-founder and Board Member, BioE2E
- Named to the 2009-2012 editions of the "Rising Stars" list published by Northern California Super Lawyers
- Co-author with A.J. Diamonti, P.M. Guy, C. Ivanof, C. Sweeney, and K.L. Carray, "An RBCC Protein Implicated in Maintenance of Steady-state Neuregulinn Receptor Levels," 99(5) Proceedings of the National Academy of Sciences of the United States of America 2866-71, 2002
- Co-author with T.E. Ciotti, "Genomics-Based Intellectual Property Portfolios," Commemorative Issue of I.P. Japan 217-229, 1999
- Co-author with N. Kiyotaka and A. Toker, "Association of Protein Kinase C with Type II PI4-kinase and PI-4,5-kinase," 273 Journal of Biological Chemistry 23126-33, 1998
- Co-author with F. Berditchevski, K.F. Tolias, C.L. Carpenter, and M.E. Hemler, "Novel Link Between Integrin, TM4SF Proteins (CD63, CD81) and PI4-kinase," 272(5) Journal of Biological Chemistry 2595-8, 1997
- Co-author with R. Meyers and L.C. Cantley, "Subcellular Locations of PI 4-kinase Isoforms," 272 Journal of Biological Chemistry 13236-41, 1997
- Co-author with L.C. Cantley, "Cloning and Characterization of a Human Phosphatidylinositol 4-kinase," 269 Journal of Biological Chemistry 28878-84, 1994
- Panelist, American Conference Institute's Life Sciences IP Due Diligence Conference, January 2006
- Chairperson, "Accelerate Preclinical Development: Outsourcing to China" Panel Discussion, BioE2E Forum, May 2005
- Chairperson, "IP Due Diligence - Inside the Mind of a VC" Panel Discussion, BioE2E Forum April 2005
- Chairperson, "The Art of Building High-Value Biotech Patent Portfolios" Panel Discussion, BioE2E Forum, June 2004
- State Bar of California
- U.S. District Court for the Northern District of California
- U.S. Court of Appeals for the Ninth Circuit
- U.S. Patent and Trademark Office
